Late-stage biopharmaceutical company Pharvaris N.V. (PHVS) is heading into the stretch where science meets the scoreboard. The company expects topline results in the fourth quarter of 2025 from RAPIDe-3, its pivotal Phase 3 trial evaluating deucrictibant for the on-demand treatment of HAE attacks.
The study reached target enrollment in March and continues to assess hereditary angioedema (HAE) attacks in enrolled participants. RAPIDe-3 is testing the immediate-release capsule formulation of deucrictibant at a 20 mg dose, which is the intended commercial dosage for acute treatment in adults and adolescents aged 12 and older.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.